mAb Development

Nov 29, 2017
By BioPharm International Editors
Binding Site has introduced a number of new monoclonal antibodies targeting infectious diseases, including cytomegalovirus, hepatitis (A, B, C, and D), herpes, human immunodeficiency virus (HIV), rubella, and toxoplasma.
Nov 28, 2017
By BioPharm International Editors
The acquisition gives GE Healthcare access to a nanofiber-based platform purification technology that can offer improvements in biopharmaceutical productivity.
Nov 20, 2017
By BioPharm International Editors
The agency has approved a biologic-based new molecular entity for treating hemophilia A and has expanded the indication for a leukemia drug to now treat a common form of non-Hodgkin lymphoma.
Nov 16, 2017
By BioPharm International Editors
The company’s new modules offer scalable single-pass diafiltration and were exclusively showcased during its Leadership Forum series in Westborough, MA.
Nov 16, 2017
By BioPharm International Editors
As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.
Nov 13, 2017
By BioPharm International Editors
The companies have established a joint laboratory to develop full continuous processing to manufacture high yields of monoclonal antibodies at reduced costs.
Oct 27, 2017
By BioPharm International Editors
AbbVie will pay a $205-million upfront payment and have the option to develop and commercialize two antibody targets globally.
Oct 27, 2017
By BioPharm International Editors
As part of the $900-million deal, Incyte will pay $150 million upfront to develop and commercialize an anti-PD-1 drug candidate from biopharmaceutical company, MacroGenics.
Oct 24, 2017
By BioPharm International Editors
The biopharmaceutical company has received a $4.2-million grant from the Bill & Melinda Gates Foundation to invest in the development of new treatments for Enterotoxigenic Escherichia coli infections, a bacterial cause of diarrhea in the developing world.
Oct 18, 2017
By BioPharm International Editors
The partnership and the formation of the institute intend to bring together industry, academia, and regulators to tackle challenges and provide solutions for continuous manufacturing.
native1_300x100
lorem ipsum